P1-265

Dynamics in blood pressure after pubertal suppression with **GnRH** analogs followed by testosterone treatment in transgender male adolescents

Liat Perl, MD¹, Anat Segev Becker, MD¹, Galit Israeli, MD¹, Erella Elkon-Tamir, MD^{1,2}, Naomi Weintrob, MD^{1,2}, Asaf Oren, MD^{1,2}

¹Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, affiliated with ² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel



Disclosure Statement: All authors have nothing to declare

BACKGROUND

In 2017, the Endocrine Society published guidelines for the hormonal treatment of gender dysphoria.

Adolescents who meet diagnostic criteria for gender dysphoria undergo pubertal suppression using gonadotropin-releasing hormone analogs (GnRHa) and induction of puberty with gender-affirming hormonal therapy (estrogen or testosterone).

The Endocrine Society Clinical Practice Guidelines recommend blood pressure (BP) monitoring before and during treatment with GnRHa and/ or treatment with testosterone.

Recommendations regarding GnRHa and blood pressure monitoring are based on a few case reports of hypertension during GnRHa treatment in precocious puberty in cis-gendered individuals.

In the transgender youth population, there is a single case series describing three cases of GnRHa-induced arterial hypertension in adolescent natal girls with gender dysphoria, one patient also developed increased intracranial pressure and papilledema.

AIMS

• To examine BP changes in transgender male adolescents treated with GnRHa and after the addition of testosterone.

STUDY DESIGN, PATIENTS & METHODS

Design: Retrospective, single-center, observational study from the Israeli Pediatric Gender Dysphoria Clinic


Patients: All consecutive transgender male adolescents who were treated solely with GnRHa for at least 2 months

Data: Data extracted from medical records included vital signs, anthropometric measurements, and hormonal levels (LH, FSH, estradiol and testosterone)

Outcome measures: Systolic and diastolic BP percentiles at baseline, after GnRHa and after testosterone treatment

RESULTS

- 15 transgender males, mean age at baseline was 14.4 \pm 1.0 years and Tanner 5 stage of puberty (13 subjects)
- GnRHa was administered for a mean period of 3 ± 1 months
- Testosterone treatment, in 9 transgender males was added at a mean age of 15.1 ± 0.9 years
- Diastolic BP percentiles increased significantly after GnRHa treatment
- Diastolic BP percentiles decreased significantly after adding testosterone therapy, only after adjusting for the change in BMI SDS
- No significant correlations were found between BP percentiles and estrogen, LH or FSH levels



Testosterone (nmol/L)	1.4 ± 1.2	0.4 ± 0.4	0.03	0.4 ± 0.5	7.1 ± 4.6	0.007	1 Baseline	2 GnRHa	3 Testosterone
Data are presented as r	nean and SD, s	tatistical analys	sis by ANOV	A, ANCOVA and	paired T test				
DISCUSSION									
Our preliminary fi	ndings sugg	est that pub	pertal sup	pression wit	th GnRHa in	creases dia	astolic BP in transgender m	ale adolescent	ts and that induction of
puberty with genc	ler-affirmin	g testostero	ne treatn	nent restore	s diastolic B	P percenti	les.		
One plausible explanation in which GnRHa might cause hypertension is the abrupt decline in estrogen and progesterone in pubertal trans male. Estrogen									
and progesterone influence the vascular system inducing vasodilatation, and so, their decline might reduce this effect.									
Induction of puberty with gender-affirming testosterone treatment might restore and lower diastolic BP percentiles through local aromatase activity in									
vascular tissue, th	us increasi	ng estrogen	levels an	d vasodilata	tion.				
Further studies with larger cohorts are needed to elucidate the effect of BP dynamics in gender dysphoric adolescents on the metabolic and cardiovascula									
consequences in y	oung adult	hood.							



Liat Perl

Sex differentiation, gonads and gynaecology or sex endocrinology

Poster presented at:

